Figure 1: Expression of Oct2, BCL6, IRF8, OCAB and PU.1 in DLBCL lymph node biopsies by immunohistochemistry. A DLBCL patient biopsy with high Oct2, BCL6, IRF8, OCAB and PU.1 expression in lymphoma cells nuclei (left). A DLBCL patient biopsy with high Oct2, BCL6 and IRF8 and low OCAB and PU.1 expression (right).